Cencora Inc's COR, formerly AmerisourceBergen Corporation, Q4 FY23 adjusted EPS reached $2.86, up from $2.60 Y/Y, beating the consensus of $2.80.
In the fourth quarter, revenue was $68.9 billion, up 12.7% Y/Y, beating the consensus of $66.02 billion, primarily due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.
The increase reflects a 13% increase in revenue within U.S. Healthcare Solutions and a 9.5% increase in revenue within International Healthcare Solutions.
Adjusted gross profit was $2.4 billion, up 6.2% Y/Y, with the margin down 13 basis points to 3.71%.
Adjusted gross profit margin reached 3.34% in Q4, a decrease of 10 basis points from Q4 FY22.
The decrease was due to the decline of U.S. Healthcare Solutions' gross profit margin as a result of increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, and lower sales of government-owned COVID-19 treatments, which have higher gross profit margins.
Adjusted operating income margin was 1.16%, down 5 basis points compared to the prior year quarter.
Guidance: Cencora expects FY24 revenue growth of 7%-10% on a constant currency basis.
U.S. Healthcare Solutions revenue growth to be 7%-10%, with International Healthcare Solutions revenue growth of around 4%-8%.
The company sees FY24 adjusted EPS of $12.70-$13.00 compared to the consensus of $12.86.
Price Action: COR shares are down 2.73% at $192.35 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.